The biopharmaceutical company, which recently received $106m in equity from Merck, has raised an additional $57.5m, taking its overall funding to almost $295m.

NGM Biopharmaceuticals, a US-based biotechnology company backed by pharmaceutical firm Merck, has closed a $57.5m series D round.

The syndicate of new and existing investors that provided the cash includes venture capital firms The Column Group, Prospect Ventures and Topspin Partners, and Tichenor Ventures, the investment vehicle for McHenry T. Tichenor, Jr.

The funding was secured a month after Merck paid $106m for a 15% stake in NGM as part of a research and development deal that also included a…